BACKGROUND: Irradiative sterilization of clinical specimens prior to chemical laboratory testing provides a way to not only sterilize pathogens and ensure laboratorian safety but also preserve sample volume and maintain compatibility with quantitative chemical diagnostic protocols. Since the compatibility of clinical biomarkers with gamma irradiation is not well characterized, a subset of diagnostic biomarkers ranging in molecular size, concentration, and clinical matrix was analyzed to determine recovery following gamma irradiation. METHODS: Sample irradiation of previously characterized quality control materials (QCs) at 5 Mrad was carried out at the Gamma Cell Irradiation Facility at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. Following irradiation, the QCs were analyzed alongside non-irradiated QCs to determine analyte recovery between dosed and control samples. RESULTS: Biomarkers for exposure to abrin, ricin, and organophosphorus nerve agents (OPNAs) were analyzed for their stability following gamma irradiation. The diagnostic biomarkers included adducts to butyrylcholinesterase, abrine, and ricinine, respectively, and were recovered at over 90% of their initial concentration. CONCLUSIONS: The results from this pilot study support the implementation of an irradiative sterilization protocol for possible mixed-exposure samples containing both chemical and biological threat agents (mixed CBTs). Furthermore, irradiative sterilization significantly reduces a laboratorian's risk of infection from exposure to an infectious agent without compromising chemical diagnostic testing integrity, particularly for diagnostic assays in which the chemical analyte has been shown to be fully conserved following a 5 Mrad irradiative dose. Published by Oxford University Press on behalf of the American Association for Clinical Chemistry 2020. This work is written by US Government employees and is in the public domain in the US.
BACKGROUND: Irradiative sterilization of clinical specimens prior to chemical laboratory testing provides a way to not only sterilize pathogens and ensure laboratorian safety but also preserve sample volume and maintain compatibility with quantitative chemical diagnostic protocols. Since the compatibility of clinical biomarkers with gamma irradiation is not well characterized, a subset of diagnostic biomarkers ranging in molecular size, concentration, and clinical matrix was analyzed to determine recovery following gamma irradiation. METHODS: Sample irradiation of previously characterized quality control materials (QCs) at 5 Mrad was carried out at the Gamma Cell Irradiation Facility at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. Following irradiation, the QCs were analyzed alongside non-irradiated QCs to determine analyte recovery between dosed and control samples. RESULTS: Biomarkers for exposure to abrin, ricin, and organophosphorus nerve agents (OPNAs) were analyzed for their stability following gamma irradiation. The diagnostic biomarkers included adducts to butyrylcholinesterase, abrine, and ricinine, respectively, and were recovered at over 90% of their initial concentration. CONCLUSIONS: The results from this pilot study support the implementation of an irradiative sterilization protocol for possible mixed-exposure samples containing both chemical and biological threat agents (mixed CBTs). Furthermore, irradiative sterilization significantly reduces a laboratorian's risk of infection from exposure to an infectious agent without compromising chemical diagnostic testing integrity, particularly for diagnostic assays in which the chemical analyte has been shown to be fully conserved following a 5 Mrad irradiative dose. Published by Oxford University Press on behalf of the American Association for Clinical Chemistry 2020. This work is written by US Government employees and is in the public domain in the US.
Authors: Brooke G Pantazides; Caroline M Watson; Melissa D Carter; Brian S Crow; Jonas W Perez; Thomas A Blake; Jerry D Thomas; Rudolph C Johnson Journal: Anal Bioanal Chem Date: 2014-03-07 Impact factor: 4.142
Authors: Rudolph C Johnson; Sharon W Lemire; Adrian R Woolfitt; Maria Ospina; Kerry P Preston; Carl T Olson; John R Barr Journal: J Anal Toxicol Date: 2005-04 Impact factor: 3.367
Authors: A C Ferraz; M E Angelucci; M L Da Costa; I R Batista; B H De Oliveira; C Da Cunha Journal: Pharmacol Biochem Behav Date: 1999-07 Impact factor: 3.533
Authors: Leigh Ann Graham; Darryl Johnson; Melissa D Carter; Emily G Stout; Huseyin A Erol; Samantha L Isenberg; Thomas P Mathews; Jerry D Thomas; Rudolph C Johnson Journal: Biomed Chromatogr Date: 2016-10-09 Impact factor: 1.902
Authors: Samantha L Isenberg; Melissa D Carter; Michael A Miller; Aleksandra I Noras; Mike A Mojica; Sean T Carlsen; Chinthaka P Bulathsinghala; Jerry D Thomas; Rudolph C Johnson Journal: J Anal Toxicol Date: 2018-11-01 Impact factor: 3.367